Price Chart

Executive Summary

Soligenix filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity by $2.5 million, bringing total authorized under the Rodman & Renshaw sales agreement to $8.906 million. The company has already sold approximately $6.234 million of shares under prior supplements, meaning up to $2.672 million in additional common stock could be issued. For a $9 million market cap company, this represents potential dilution of ~28% and signals ongoing cash needs.

Key Facts

• ATM offering capacity increased by $2.5 million to a total of $8.906 million under the Sales Agreement with Rodman & Renshaw LLC.
• Prior sales of approximately $6.234 million of common stock had been completed under earlier prospectus supplements covering up to $6.406 million.
• Up to $2.672 million in additional shares may be sold at market prices, representing roughly 28% of the current $9 million market cap.

Financial Impact

Potential dilution of up to ~28% of current market cap if the full $2.5 million in additional shares are sold at current prices.

Risk Factors

• Further dilution from ongoing ATM sales could pressure the stock price.
• Cash burn may necessitate additional equity raises beyond this ATM increase.
• Lack of revenue or near-term catalysts increases reliance on equity financing.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status